Table 3.
Subgroup and meta-regression analysis examining factors for successful superparamagnetic iron oxide nanoparticle-guided sentinel lymph node detection
| Subgroup analysis | Meta-regression analysis | |||
|---|---|---|---|---|
| Risk ratio | P | Coefficient b | P | |
| Probe | ||||
| ȃSentimag® | 1.007 (0.994, 1.019) | 0.289 | ||
| ȃTokyo probe | 1.003 (0.924, 1.088) | 0.941 | ||
| SPIO | ||||
| ȃFerucarbutran | 1.003 (0.924, 1.088) | 0.941 | ||
| ȃMagtrace® | 1.010 (0.992, 1.029) | 0.277 | ||
| ȃSienna + ® | 1.004 (0.988, 1.021) | 0.598 | ||
| Injection site | –0.0083 (–0.0663, 0.0498)* | 0.781 | ||
| ȃSubareolar | 1.000 (0.991, 1.010) | 0.957 | ||
| ȃPeritumoral | 1.118 (0.982, 1.272) | 0.091 | ||
| Timing of injection | 0.0544 (0.0042, 0.1045)† | 0.034 | ||
| ȃPeroperative | 0.999 (0.990, 1.008) | 0.819 | ||
| ȃPreoperative | 1.116 (1.020, 1.222) | 0.017 | ||
| Setting | ||||
| ȃAfter neoadjuvant therapy | 1.021 (0.975, 1.069) | 0.375 | ||
| ȃUpfront | 1.005 (0.992, 1.018) | 0.442 | ||
| Comparison | ||||
| ȃPaired | 1.007 (0.995, 1.020) | 0.251 | ||
| ȃUnpaired | 0.956 (0.893, 1.024) | 0.197 | ||
| Subgroup | –0.3627 (–0.5967, –0.1287)‡ | 0.002 | ||
| ȃStandard SLNB | 1.002 (0.993, 1.011) | 0.661 | ||
| ȃDelayed SLNB | 1.528 (1.216, 1.922) | < 0.001 | ||
| Injection volume (ml) | ||||
| ȃ0.5 | 1.032 (0.981, 1.086) | 0.227 | ||
| ȃ1.0 | 1.016 (0.968, 1.067) | 0.522 | ||
| ȃ1.5 | 0.988 (0.959, 1.017) | 0.407 | ||
| ȃ2.0 | 1.042 (0.974, 1.115) | 0.231 | ||
| ȃ5.0 | 1.000 (0.988, 1.013) | 0.959 | ||
Values in parentheses are 95% confidence intervals. Coefficient for *subareolar injection, †preoperative injection or ‡standard sentinel lymph node dissection. SPIO, superparamagnetic iron oxide nanoparticles; SLNB, sentinel lymph node biopsy.